• Journal of Radiation Protection and Research
• /
• 제39권2호
• /
• pp.96-102
• /
• 2014

소변시료 바이오어세이는 분석설비가 비교적 간단하고 시료 채취가 용이하여 내부피폭선량 평가를 위하여 널리 사용되고 있는 대표적인 간접측정법이다. 본 연구에서는 소변시료 바이오어세이 결과에 대해 보다 객관적인 성능검사를 수행하기 위하여 미국 NIST에서 주관한 NRIP (NIST raiochemistry inercomparison pogram)에 참여한 결과를 소개하였다. 60일간의 분석기간 동안 인공합성소변으로 제작된 검사시료의 방사능분석결과를 보고하는 cstomary exercise에서는 12가지 방사성핵종에 대한 측정 결과 ANSI N13.30에서 제시하는 성능검사 기준을 모두 만족하는 것으로 확인되었다. 비상상황에 대비하여 8시간 이내에 방사능분석결과를 신속하게 보고하는 eergency preparedness exercise에서는 9가지 방사성핵종에 대하여 -35 ~ 45%의 차이를 나타내어 확인된 오차범위 내에서 비상시 신속한 내부피폭 분류에 적용하기에 적합한 것으로 확인되었다.

• 한국원자력학회:학술대회논문집
• /
• 한국원자력학회 2001년도 춘계학술발표회요약집
• /
• pp.401.1-401
• /
• 2001

• 한국대기환경학회지
• /
• 제3권1호
• /
• pp.27-33
• /
• 1987

삼중수소 ($^{3}H$) 에 관한 환경 및 생물학상의 연구는 1950년대 중반부터 선진국에서 수행되오고 있다. 삼중소소에 대한 잠재적 노출의 경우 통상적 처리절차는 삼중수소의 신체부하량이라고 일컬어지는 이른바 신체내에 축적된 삼중수소의 양을 결정하기 위하여 삼중수소수로서 오줌속에 포함되는 삼중수소 방사능의 생리분석이다. 전신에 있어서 삼중수소의 최대허용신체부하량은 신체조직에 대하여 약 $30{\mu}Ci/{\ell}$ 이다. 생리분석에서 오줌속에 삼중수소를 검출하는데 가장 보편적인 조사준위(照射准尉)는 최대허용신체부하량의 1/10 이다. 이러한 생리분석 연구계획을 위해서는 소광보정(消光補正) 곡선을 그리는 것이 가장 우선적이다. 이것은 검뇨용 오줌의 색깔이 일정하지 않기 때문에 필요한 것이다. 이 경우에서 소광효과는 주로 오줌시료에 의한 섬광빛의 흡수에 기인된다. 소광보정곡선으로 판단된 공식은 통계적 근거에서 최소자승법에 의하여 Y (%) = 0.771 + 1.836 ${\tmes}10^{-4}$X(count)로 얻어졌다. 여기서 Y는 섬광계수 효율로서 약 12%에서 31% 범위의 값으로 나타났다. 본 논문에서는 삼중수소의 생물학적 반감기와 신체계통적으로 분포된 삼중수소에 적용되고 있는 정체(停滯) 공식에 관한 간략한 이론에 관하여 서술된다.

• Biomolecules & Therapeutics
• /
• 제5권2호
• /
• pp.179-186
• /
• 1997

The pharmacokinetics and tissue distribution of DWP20373, a novel fluoroquinolone, were examined in rats and beagle dogs after a single intravenous and oral administration. Analysis of DWP20373 in plasma, tissue, and urine was performed by both HPLC and microbiological assay. The plasma drug concentration declined biexponentially both rats and beagle dogs. In the rats, the terminal drug elimination half-life (t$_{1}$2$\beta$/) was 64 min (IV) and 57 min (PO) by bioassay, and 76 min (IV) and 77 min (PO) by HPLC. Whereas in beagle dogs, t$_{1}$2$\beta$/ was 196 min (IV) and 350 min (PO). The volume of distribution at steady-state (Vd$_{ss}$ ) was 811 ml/kg (bioassay) and 2061 ml/kg (HPLC) in rats, and 2738 ml/kg (bioassay) in beagle dogs. The total body clearance (Cl$_{t}$) of DWP20373 was 10 ml/min/kg (bioassay) and 7 ml/min/kg (HPLC) in rats, and 11 m1/min/kg (bioassay) in beagle dogs. The extent of bioavailability after oral administration was 49% (bioassay) and 67% (HPLC) in rats, and 84% (bioassay) in beagle dogs. The 24-h urinary recovery, measured by bioassay, was 2.7% after oral dosing and 5.5% after intravenous dosing in rats. Serum protein binding ratio determined at 27g/ml was 78%. This drug was also distributed in tissues in the decreasing order of liver, kidney, spleen, lung, heart, and muscle determined at 30 min after oral administration.on.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2005년도 춘계 국제심포지엄 및 학술대회
• /
• pp.176-176
• /
• 2005

• 한국미생물·생명공학회지
• /
• 제24권4호
• /
• pp.472-477
• /
• 1996

Natural human epidermal growth factor (nhEGF) was purified from pregnant human urine by benzoic acid adsorption, DEAE-Sepharose ion exchange, and immunoaffinity chromatography. The purified nhEGF was further separated into four fractions using Bondapak C$_{18}$ HPLC system. Following characterization by Western blot analysis and double immu- nodiffusion, we found that each fraction corresponds to four derivatives of the nhEGF. For biological analysis of nhEGF, we optimized the labeling time and serum concentration for the incorporatioin of 5-bromo-2'-deoxy uridine (BrdU), a non-radioactive alternative for [$^{3}$H]-thymidine uptake, into NIH 3T3 cells. The DNA synthesis of NIH 3T3 cells was gradually increased at the nhEGF concentrations between 0.1 - 10 ng/ml in the Dulbecco's Modified Eagles Medium (DMEM) containing 0.2% Fetal calf serum (FCS). When we assayed the biological activity of four fractions, the activity of the second fraction was superior to that of the others. Based on the results from the HPLC analysis spiked with recombinant human epidermal growth factor (rhEGF) and amino acid sequencing, we concluded that the second fraction was nhEGF and the other three fractions were the derivatives of nhEGF. In addition, the proportion of nhEGF was approximately 46% is compared with that of the other three derivatives.

• Biomolecules & Therapeutics
• /
• 제5권3호
• /
• pp.284-291
• /
• 1997

The pharmacokinetics and tissue distribution of DWP20367 (1-cyclopropyl-6-fluoro-8-chloro-7-(2, 7-diazabicyclo[3,3,0]tract-4-ene-7-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid), a novel fluoroquinolone, were examined in rats and beagle dogs after a single intravenous and oral administration. Analysis of DWP20367 in plasma, tissue, and urine was determined by both HPLC and microbiological assay (bioassay). The plasma concentration-time curves of the drug in rats and beagle dogs were biexponentially declined. The terminal half-life (t$_{1}$2$\beta$/) of the drug in rats was about 60.1 $\pm$7.3 min (i.v.) and 61.3 $\pm$ 12.4 min (p.o.) in bioassay, and 86.3 $\pm$19.8 min (i.v.) and 50.9$\pm$ 14.9 min (p.o.) in HPLC. In beagle dogs, half-life of the drug determined by bioassay was about 121.8$\pm$6.2 min (i.v.) and 111.0$\pm$7.6 min (p.o.). The volume of distribution at steady-state (Vd$_{ss}$ ) was 243.8$\pm$74.1 ml/kg (bioassay) and 339.2$\pm$84.3 ml/kg (HPLC) in rats, and 1587.5 $\pm$536.9 ml/kg (bioassay) in beagle dogs. The total body clearance (Cl$_{t}$) of DWP20367 was 3.4 $\pm$ 0.4 ml/min/kg (bioassay) and 2.4$\pm$0.4 ml/min/kg (HPLC) in rats, and 12.3$\pm$ 1.0 ml/min/kg (bioassay) in beagle dogs, respectively. The extent of bioavailability after oral administration was 89.1%(bioassay) and 79.9% (HPLC) in rats, and 78.7% (bioassay) in beagle dogs. Urinary recovery (24-h) assayed by bioassay was 0.7% (p.o.) and 1.2% (i.v.) in rats, and 0.8% (p.o.) and 1.0% (i.v.) in beagle dogs. In rats, 24-h fecal recovery determined by bioassay was 11.2% (p.o.) and 0.1% (i.v.). Rat and human serum protein binding ratios at 2$\mu$g/ml were about 90~91%. This drug determined by bioassay was also distributed by the order of liver, kidney, lung, heart, spleen and muscle 30 min after oral administration.on.

• Nuclear Engineering and Technology
• /
• 제56권6호
• /
• pp.2050-2056
• /
• 2024

Handling of radioisotopes may cause external and internal contamination to occupational workers while using radiation for medical purposes. This research aims to monitor the internal hazard of occupational workers who handle ¹³¹I. Two methods are used: in vivo or direct method and in vitro or indirect method. The in vivo or direct method was performed by assessing thyroid intake with a thyroid uptake monitoring machine. The in vitro or indirect method was performed by assessing urine samples with the help of a gamma-ray spectroscopy practice using a High-Purity Germanium (HPGe) Detector. In this study, fifty-nine thyroid counts and fifty-nine urine samples were collected from seven occupational workers who were in charge of ¹³¹I at the National Institute of Nuclear Medicine and Allied Sciences (NINMAS), Dhaka. The result showed that the average annual effective dose of seven workforces from thyroid counts were 0.0208 mSv/y, 0.0180 mSv/y, 0.0135 mSv/y, 0.0169 m Sv/y, 0.0072 mSv/y, 0.0181 mSv/y, 0.0164 mSv/y and in urine samples 0.0832 mSv/y, 0.0770 mSv/y, 0.0732 mSv/y, 0.0693 mSv/y, 0.0715 mSv/y, 0.0662 mSv/y, 0.0708 mSv/y.The total annual effective dose (in vivo and in vitro method) was found among seven workers in average 0.1039 mSv/y, 0.0950 mSv/y, 0.0868 mSv/y, 0.0862 mSv/y, 0.0787 mSv/y, 0.0843 mSv/y, 0.0872 mSv/y. Following the rules of the International Commission on Radiological Protection (ICRP), the annual limit of effective dose for occupational exposure is 20 mSv per year and the finding values from this research work are lesser than this safety boundary.

• 약학회지
• /
• 제39권3호
• /
• pp.223-230
• /
• 1995

The phannacokinetics and tissue distribution of DWQ-013, a new quinolone, were examined in rats and mice following a single intravenous and oral administration. DWQ-013 in plasma and urine was determined by both HPLC and microbiological assay. The plasma concentration of the drug declined biexponentially. The terminal half life of the drug was 11.11$\pm$0.14 hour after intravenous dosing. The volume of distribution at terminal elimination phase(Vd$_\beta$) and total clearance of the drug were 1.29$\pm$0.15 l/kg and 0.78$\pm$0.09 l/h/kg. The bioavailability of DWQ-013 after oral administration was 56.0% (HPLC) and 77.2%(bioassay), respectively. Twelve-hour urinary recovery of drug was measured by HPLC and bioassay to 0.035$\pm$0009% and 4.71$\pm$066% after oral dosing, to 0.055$\pm$0.014% and 7.65$\pm$1.53% after intravenous dosing, which may indicate the presence of biologically active metabolites. Binding of the drug to plasma proteins ranged from 97%~99% at various concentrations. The drug was highly distributed in order of liver, kidney and lung after 1.5 hours in mice.

• Journal of Radiation Protection and Research
• /
• 제31권3호
• /
• pp.135-140
• /
• 2006

비밀봉 방사성물질의 취급 사고시 방사성핵종은 흡입과 취식의 두 가지 경로로 섭취될 수 있다. 이때 일상 감시처럼 하나의 섭취경로만 가정하여 예탁유효선량을 평가하면 심각한 오차를 유발할 수 없다. 이러한 잠재 오차를 제시하기 위해 총 섭취에 대한 흡입섭취의 비율을 달리할 때 예탁유효선량의 변동을 분석하였다. $^{241}Am$(AMAD 5 ${\mu}m$, 흡수형 M)을 대상으로 핵종의 생물역동학적 모델과 데이터를 이용하여 여러 흡입섭취 분율에서 폐, 소변 및 대변에 대한 바이오어세이 측정치를 모의하였다. 섭취 3일 후 예상 측정치를 이용하고 단일 경로 섭취를 가정한 경우 평가된 예탁유효선량의 잠재 오차는 -100%에서부터 많게는 +34,000%에 이르는 것으로 나타났다. 흡입섭취가 있을 때 대변만 분석하면 큰 오차가 발생하였다. 섭취경로 오판에 따르는 선량평가의 오차를 줄이기 위해 두 종류의 바이오어세이를 이용하는 전략을 제안하였다.